Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib in Progressive Metastatic Neuroendocrine Tumors
NCT00131911Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jun 2005
- Primary completion
- Oct 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of sorafenib in Neuroendocrine Neoplasm (NEN), sponsored by National Cancer Institute. Primary endpoint: Confirmed Response Rate up to 2 years. Started Jun 2005; status: completed.
02
Drugs
sorafenib
03
Conditions
Neuroendocrine Neoplasm (NEN)
Beyond the preview
Go deeper on NCT00131911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00131911.